| |
| |
|
| Insider
Information: |
Kumar Neil |
| Relationship: |
Director |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
4,897,443 |
|
|
Indirect Shares
|
31,586,701 |
|
|
| Direct
Value |
$133,994,040 |
|
|
|
Indirect Value
|
$3,058,322,020 |
|
|
| Total
Shares |
36,484,144 |
|
|
| Total
Value |
$3,192,316,061 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 481.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eidos Therapeutics, Inc. |
EIDX |
Chief Executive Office... |
2018-06-22 |
0 |
2019-07-03 |
24,575,501 |
Premium* |
|
|
Bridgebio Pharma, Inc. |
BBIO |
|
2024-05-16 |
4,897,443 |
2024-05-16 |
2,008,408 |
Premium* |
|
|
Lianbio |
LIAN |
Director |
|
0 |
2021-10-29 |
5,002,792 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
72 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-03-03 |
4 |
AS |
$10.96 |
$1,315,224 |
I/I |
(120,000) |
1,252,722 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-02-03 |
4 |
AS |
$11.01 |
$1,320,696 |
I/I |
(120,000) |
1,372,722 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-11-16 |
4 |
D |
$28.86 |
$1,463,115 |
D/D |
(50,697) |
4,864,749 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-08-17 |
4 |
AS |
$28.59 |
$1,473,784 |
D/D |
(51,552) |
4,813,197 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-11-17 |
4 |
AS |
$29.10 |
$1,500,038 |
D/D |
(51,552) |
4,813,197 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-08-16 |
4 |
D |
$29.80 |
$1,510,800 |
D/D |
(50,698) |
4,864,749 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2020-04-01 |
4 |
AS |
$25.52 |
$1,631,362 |
I/I |
(62,117) |
2,583,255 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-05-03 |
4 |
AS |
$14.18 |
$1,701,744 |
I/I |
(120,000) |
1,012,722 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2020-07-02 |
4 |
AS |
$30.22 |
$1,706,022 |
I/I |
(56,445) |
2,165,372 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2024-02-16 |
4 |
D |
$37.21 |
$1,783,178 |
D/D |
(47,922) |
4,867,524 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2020-08-03 |
4 |
AS |
$27.23 |
$1,801,306 |
I/I |
(66,057) |
2,099,315 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-04-05 |
4 |
AS |
$15.46 |
$1,855,656 |
I/I |
(120,000) |
1,132,722 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• • – |
2020-02-04 |
4 |
AS |
$34.55 |
$1,898,387 |
I/I |
(54,951) |
2,796,265 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2020-06-01 |
4 |
AS |
$29.13 |
$2,335,390 |
I/I |
(80,000) |
2,325,372 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2020-05-05 |
4 |
AS |
$30.86 |
$2,469,482 |
I/I |
(79,600) |
2,405,372 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
See Remarks |
• • – |
2020-01-03 |
4 |
AS |
$32.14 |
$2,702,956 |
I/I |
(83,939) |
2,885,372 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2020-07-01 |
4 |
AS |
$30.63 |
$2,705,335 |
I/I |
(87,025) |
2,221,817 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2020-03-02 |
4 |
AS |
$31.88 |
$3,226,883 |
I/I |
(99,953) |
2,665,419 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Executive Officer |
• • • |
2018-06-22 |
4 |
D |
$17.00 |
$3,599,954 |
I/I |
(211,762) |
18,614,655 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Executive Officer |
• • • |
2018-06-22 |
4 |
B |
$17.00 |
$17,000,000 |
I/I |
1,000,000 |
19,614,655 |
2.64 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Executive Officer |
• • • |
2019-07-03 |
4 |
B |
$29.90 |
$26,382,796 |
I/I |
882,353 |
24,575,501 |
2.64 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Chief Executive Officer |
• • • |
2019-05-24 |
4 |
B |
$25.93 |
$28,622,779 |
I/I |
1,103,848 |
23,693,148 |
2.64 |
- |
|
72 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
